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Introduction
Attempts to improve early detection of breast cancer and
to provide individualized breast cancer risk assessment
include methods to examine cellular material from the
apparently normal breast. Although mammographic
screening is an effective tool for detecting breast cancer,
it has inherent and well described limitations [1]. In addi-
tion, mathematical models such as the Gail Model have
been developed to predict breast cancer risk [2], but
such models are better at assessing population-based
risk rather than individual risk. Tamoxifen decreases risk
for development of breast cancer by 50% in women who
are at increased risk for the disease [3]. Unfortunately,
tamoxifen has rare but serious side effects; therefore,
additional information to refine risk stratification would
be useful.
Nipple aspirate fluid (NAF) can be obtained from non-
lactating women by simple suction methods. Several
groups have examined the cytology of NAF in attempts
to improve detection of breast cancer and predict risk
based on cellular findings [4–7]. Although abnormal
cytology in NAF is predictive of subsequent develop-
ment of breast cancer, with a relative risk of 2.5–5 at
12.5 years [5], cellular yield from this technique is low.
Atypia seen in fine-needle aspiration (FNA) of the
breast, in which multiple aspirations are performed and
pooled for analysis, also is associated with an increased
risk for breast cancer, with a relative risk of 5 at
45 months [8]. The relative risk seen with atypia
detected either in NAF or in FNA is consistent with that
observed for atypical ductal hyperplasia when detected
in surgical specimens [9–13] and suggests that atypia
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Ductal lavage (DL) permits noninvasive retrieval of epithelial cells from the breast. Clinical development
of this technique has been fueled largely by its potential, as yet unproven, to improve detection of
breast cancer and definition of individual risk for development of breast cancer. Early studies
demonstrate the feasibility of performing this technique, provide data on cellular yield and findings, and
demonstrate the ability to measure molecular markers in DL fluid. However, the sensitivity and
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approved by the US Food and Drug Administration, DL is still best utilized in the setting of clinical trials
designed to resolve issues of sensitivity, specificity, and localization.
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as identified by these methods may help further define
individual risk for breast cancer.
Ductal lavage
In an effort to improve upon NAF and FNA, a DL system
has been devised. This method involves suction of the
nipple in order to localize NAF-yielding duct(s). NAF-
producing ducts can then be cannulated using a micro-
catheter (Pro*Duct Health Inc., Menlo Park, CA, USA) and
lavaged with saline in order to retrieve duct epithelial cells
for cytological analysis. NAF-producing ducts are targeted
for logistical reasons (NAF allows for the localization of the
ductal orifice and subsequent cannulation) and because
data suggest that women who produce NAF are at
increased risk for the development of breast cancer [5].
Two recent studies [14,15] examined applications of DL,
including the ability of DL versus NAF to detect abnormal
breast epithelial cells and the ability to use molecular tech-
niques such as methylation-sensitive polymerase chain
reaction (MSP) in DL specimens to identify abnormal cells.
Detection of abnormal cytology
Dooley et al. [14] examined 507 women with an elevated
risk for breast cancer (based on elevated Gail index, prior
history of invasive or noninvasive breast cancer, or pres-
ence of a BRCA mutation), but with low-suspicion physi-
cal examinations and mammograms, by performing nipple
aspiration followed by DL. NAF and DL samples were
obtained from 82 and 75% of women, respectively. The
DL specimens were much more likely to have adequate
cellular material for cytologic diagnosis (78% versus 27%)
and had higher median epithelial cell yields (13,500
epithelial cells per duct versus 120 epithelial cells per
breast). Abnormal cytology was detected in 24% of DL
samples: 17% were mildly atypical, 6% were markedly
atypical, and 0.5% were termed malignant. For NAF these
percentages were 6, 3, and 0.5%, respectively. The two
women with malignant cytology on DL were the same two
with malignant cytology on NAF. DL was reasonably well
tolerated, with a median pain rating of 24 versus 8 for
nipple aspiration (scale 0–100). In addition to breast pain,
breast engorgement, and ecchymoses, two possible
cases of cellulitis were identified. Eleven patients with
abnormal cytology had further diagnostic studies, includ-
ing imaging, ductoscopy and surgery. Four were diag-
nosed with ductal carcinoma in situ (DCIS). Details
regarding the corresponding DL cytology of those patients
have not been reported, or has the corresponding follow
up in the two women with malignant cytology.
Molecular markers
In addition to cytology, DL may permit analysis of molecu-
lar markers associated with breast carcinomas. In a report
by Evron et al. [15], specimens (excised tumors, duct
endoscopy fluid, or DL samples) were examined by MSP
for Cyclin D2, RAR-β and Twist genes. At least one of the
three genes was methylated in 96% of surgically excised
primary breast tumors and in 57% of DCIS lesions, but in
no normal breast tissue samples, demonstrating high sen-
sitivity and specificity of this technique. Thirty-seven
patients with biopsy-proven breast cancer underwent duct
endoscopy, with direct visualization of the ducts, and
lavage; the specimens were evaluated using MSP. In the
20 women in whom residual invasive carcinoma was iden-
tified histologically at re-excision, 17 (85%) also had at
least one methylated marker present in the duct fluid. Of
the 13 women with residual DCIS or atypical ductal hyper-
plasia identified histologically at re-excision, four (30%)
had a methylated marker. All four women with negative re-
excisions also had negative MSP.
Using cytologic examination and MSP, Evron et al. [15]
also examined DL fluid from 56 women who were part of
the NAF versus DL study described above [14]. Six of
those women had DL specimens classified by cytology as
atypical with substantial changes, or as malignant. Four of
these six cases had a least one positive marker by MSP
(67%). Two of these four women (with both abnormal
cytology and positive MSP) were further evaluated and
found to have DCIS. These data demonstrate the feasibil-
ity of detection of molecular markers in DL specimens and
suggest that DL may have a role to play in early detection.
Limitations
Data from the studies described above [14,15] demon-
strate that DL is a feasible outpatient procedure by which
cellular material can be retrieved. In a handful of cases,
evaluation of abnormal DL cytology led to a diagnosis of
DCIS that was not initially detected by physical examina-
tion or mammography. DL enables greater cellular yield
than NAF, and leads to fewer pathologic diagnoses of
‘insufficient cellular material’. In addition, DL detects signif-
icantly more atypia than does NAF. Although it is possible
that atypia from DL connotes the same risk as atypia from
NAF and FNA, this remains to be confirmed with addi-
tional studies. DL detected more cases of mild atypia than
did NAF. Far fewer cases of either marked atypia or malig-
nancy were found by either method, and the detection
rates of the two methods appeared to vary less substan-
tially than for the detection of mild atypia. Atypia found on
NAF has been reported as predictive of future breast
cancer risk [5], which suggests that NAF detects ‘the
atypia that matters’, but follow-up studies are needed to
improve our understanding of the significance of mild
atypia as detected by DL. Therefore, it is currently unclear
how findings from DL should be incorporated into risk
assessment. If a woman has previously decided not to
take tamoxifen for chemoprevention, should she be
encouraged to do so on the basis of mild atypia from a DL
sample? Given the uncertainties, the use of DL findings to
stratify patients for tamoxifen prevention should be done
within the context of a clinical trial.Second, the sensitivity and specificity of DL for the detec-
tion of invasive carcinoma is unknown. A negative DL
should not be reassuring to a woman at high risk. In the
study that established NAF atypia as a risk factor [5], the
majority of patients who eventually developed breast
cancer did not have abnormal cytology. Whether DL adds
to the sensitivity of NAF is unknown. Data do not currently
exist on the rate of abnormal cytology in non-NAF-yielding
ducts. Thus, a normal lavage should not discourage a
woman from routine screening or from taking tamoxifen for
prevention if she is otherwise a candidate.
So what does a positive DL result mean and how should it
be evaluated? Any algorithm will necessarily be based on
extrapolation from NAF, given the limited follow-up data for
DL. A practicing oncologist might view the issue as
follows; should a woman go to mastectomy if DL repeat-
edly shows markedly atypical cells and all imaging studies
are negative? Given the available data, this seems
extreme. Follow-up data from published studies and
further investigation are needed before patients can be
meaningfully informed about the implications of DL results.
Once clarified, DL may in time help to avoid unnecessary
surgery and yet detect silent tumors.
Conclusion
DL remains a promising technique for early detection of
breast cancer and for detection of premalignant lesions in
high-risk women. Nonetheless, data regarding the sensitiv-
ity and specificity of DL in detecting breast cancer, its use-
fulness in risk stratification, and the significance of mild
atypia as detected by DL are limited. The ability to perform
polymerase chain reaction amplification on ductal epithe-
lial cells retrieved by DL may allow for early detection of
molecular markers that are associated with malignant
transformation, such as promoter methylation changes or
telomerase expression. The promise of DL is great, but
many questions remain. Because of this, DL is best used
in the context of clinical trials focused on breast cancer
detection and prevention.
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